INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is one of the most common malignant tumors throughout the world with over 1.2 million new cases and 608700 deaths estimated to occur annually \[[@R1]\]. The liver is the most common site of colorectal cancer metastasis. Nearly half of CRC patients will develop colorectal liver metastases (CRLM) during the course of their disease, with 15% of patients having liver metastatic lesions at the time of diagnosis \[[@R2]\]. Surgical resection of colorectal liver metastases is a potentially curative option, with reported 5-year survival of 28--39% \[[@R3]--[@R5]\] and 10-year overall survival of over 20% \[[@R4], [@R6]\]. However, unfortunately, 70--80% of patients will relapse in two years after liver surgery, and about 80% of patients with colorectal liver metastases have unresectable disease at presentation \[[@R7]\].

To improve the prognosis of CRLM patients, it is important to improve the liver metastasis treatment outcomes. Over the past decade, the introduction of irinotecan- or oxaliplatin-based combination chemotherapy have resulted in significant improvements in objective response rates and ultimately in overall survival of unselected patients with metastatic colorectal cancer \[[@R8]--[@R10]\]. In recent years, neoadjuvant chemotherapy (NCT) has been increasingly used in the management of liver-confined metastases from CRC. For patients with initially resectable disease, the use of NCT in CRLM might increase the complete resection rate and treat the micro-metastatic disease \[[@R3], [@R11]\]. When treating unresectable liver metastases of colorectal cancer, "conversion therapy" has been applied to reduce the tumor size and facilitate resection via preoperative chemotherapy \[[@R12], [@R13]\]. In addition, NCT can be used as a test of *in vivo* chemosensitivity, and patients with extremely aggressive disease, who will progress during preoperative chemotherapy, can be spared useless surgery. As a result, neoadjuvant chemotherapy combined surgery for liver metastasis is regarded as an effective strategy in CRLM patients.

During the past decade, the understanding of the molecular pathways that involved in tumor growth and metastasis has significantly increased and with this has come the development of several molecular targeted therapies \[[@R9], [@R14]--[@R16]\]. Two options are currently available in routine clinical practice for CRLM patients: Epidermal growth factor receptors (EGFRs) antibodies and vascular endothelial growth factor (VEGF) antibodies. The efficacy of these molecular targeted agents in the treatment of unselected metastatic CRC has been extensively investigated, but whether the addition of molecular targeted agents to NCT in CRLM patients would improve response rate and hepatic resection rate remains unclear. A recent meta-analysis conducted by Qi et al \[[@R17]\] showed that the addition of targeted agents to first-line chemotherapy for unselected advanced colorectal cancer significantly improved the complete response when compared with controls. However, it is still unknown whether this benefit in response rate would translate into an improvement in hepatic resection rate and R0 hepatic resection rate for CRML patients. We thus conduct this meta-analysis of published data to compare the efficacy of NCT plus targeted agents verse NCT alone in CRLM patients.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

A total of 543 studies were identified from the database search, of which 54 reports were retrieved for full-text evaluation. 40 cohorts from 32 trials \[[@R24]--[@R54]\] met the inclusion criteria and were included in this systematic review: (Figure [1](#F1){ref-type="fig"}). Table [1](#T1){ref-type="table"} showed the characteristics of the included studies. Overall, 2099 CRLM patients were included, with a median age of 62.0 years \[95% confidence interval (CI): 59.0--62.91\] for the NCT alone group and 61.0 years (95% CI: 58.2--62.9) for the NCT plus targeted agents group. We found two randomized controlled trials comparing NCT plus cetuximab with NCT alone in CRLM patients, but no randomized controlled trials directly comparing NCT plus bevacizumab with NCT alone in these settings. Methodological quality of the included studies was fair; most studies provided adequate outcome ascertainment, enrolled a representative sample of patients, and had an acceptable length of follow-up (Figure [2](#F2){ref-type="fig"}). However, comparative evidence was at high risk of bias because we compared data across studies not within them, and selection bias was likely to be present. Assessment of publication bias was not done because data would be unreliable in view of the few studies included for each treatment group and high heterogeneity (*I*2 \> 50%) in most analyses.

![Selection process for clinical trials included in the meta-analysis](oncotarget-06-44005-g001){#F1}

###### Baseline characteristics of 39 cohort groups for meta-analysis

  Author                    Year   Study design    Patients, n   Neoadjuvant therapy               Median age, y   Initially status, n              Median PFS, months   ORR, %
  ------------------------- ------ --------------- ------------- --------------------------------- --------------- -------------------------------- -------------------- --------
  Uetake H. et al           2015   Prospective     45            mFOLFOX6+bevacizumab              62.5            Resectable,19 unresectable, 26   NR                   55.60%
  Suenaga M. et al          2015   Prospective     12            FOLFOX4+bevacizumab               60.5            Unresectable                     18.2                 75%
  Pietrantonio F. et al     2015   Retrospective   93            Chemotherapy +bevacizumab         56              NR                               NR                   78%
                                                                 Chemotherapy +cetuximab           59              NR                               NR                   85%
  Malik H. et al            2015   Retrospective   60            Chemotherapy +cetuximab           62              Unresectable                     NR                   NR
  Gruenberger T. et al      2015   Prospective     80            FOLFOXIRI +bevacizumab            63              Unresectable                     18.6                 81%
                                                                 mFOLFOX6+bevacizumab              57              Unresectable                     11.5                 62%
  Vera R et al              2014   Retrospective   95            Chemotherapy +bevacizumab         NR              Unresectable                     NR                   52%
                                                                 chemotherapy                      NR              Unresectable                     NR                   50%
  Primrose J. et al         2014   Prospective     257           Chemotherapy +cetuximab           63              Resectable                       14.1                 70%
                                                                 chemotherapy                      64              Resectable                       20.5                 62%
  Eppu T. et al             2014   Prospective     40            FOLFOX6+bevacizumab               63              NR                               9.7                  30%
  Ychou M. et al            2014   Prospective     125           chemotherapy                      NR              Unresectable                     11.9                 NR
  Takahashi T. et al        2013   Prospective     36            mFOLFOX6                          62.5            Unresectable                     9.2                  NR
  Nordlinger B et al.       2013   Prospective     171           FOXFOX4                           62              Resectable                       NR                   NR
  Ye L.C. et al             2013   Prospective     138           Cetuximab +chemotherapy           57              Unresectable                     NR                   57.10%
                                                                 chemotherapy                      59              Unresectable                     NR                   29.40%
  Nasti G. et al            2013   Prospective     39            FOLFIRI +Bevacizumab              58              Resectable                       14                   66.70%
  Ji J.H. et al             2013   Prospective     73            FOLFOX6+cetuximab                 57              Unresectable                     9.8                  72.60%
  Cvetanovic A. et al       2013   Retrospective   51            Oxaliplation-based +bevacizumab   NR              NR                               9.9                  NR
  Constantinidou A. et al   2013   Retrospective   94            Chemotherapy +bevacizumab         63              NR                               NR                   NR
                                                                 chemotherapy                      62              NR                               NR                   NR
  Leone F. et al            2013   Prospective     46            Panitumumab +XELOX                60              Unresectable                     8.5                  54%
  Wong R. et al             2011   Prospective     46            Xelox +bevacizumab                63              Unresectable, 30                 NR                   78%
  Bertolini F. et al        2011   Prospective     21            FOLFOX6+bevacizumab               NR              Unresectable                     12.5                 57%
  Nakanishi M. et al        2014   Retrospective   20            Bevacizumab +chemotherapy         NR              Resectable                       NR                   66.70%
  Garufi C. et al           2010   Prospective     43            Chemotherapy +cetuximab           61              Unresectable                     NR                   79%
  Folprecht G. et al        2010   Prospective     111           FOLFOX6+cetuximab                 65.1            NR                               NR                   68%
                                                                 FOLFIRI+ cetuximab                62              NR                               NR                   57%
  Chaudhury P. et al        2010   Retrospective   35            Chemotherapy +bevacizumab         57              NR                               NR                   65.70%
  Masi G. et al             2010   Prospective     30            FOLFOXIRI +bevacizumab            61              Unresectable                     16.9                 80%
  Skof E. et al             2009   Prospective     87            XEFIRI                            63              Unresectable                     10.3                 NR
                                                                 FOLFIRI                           62              Unresectable                     16.6                 NR
  Bathe O. et al            2009   Prospective     35            FOLFIRI                           59              Resectable                       NR                   NR
  Coskun U. et al           2008   Retrospective   35            XELOX                             58              Unresectable                     NR                   NR
  Barone C. et al           2007   Prospective     40            FOLFIRI                           58.7            Unresectable                     14.3                 NR
  Gruenberger B. et al      2008   Prospective     56            Xelox +bevacizumab                61.5            Resectable                       NR                   73%
  Min B.S. et al            2007   Prospective     23            FOLFIRI +cetuximab                NR              Unresectable                     NR                   39.10%
  Alberts S.R. et al        2005   Prospective     42            FOLFOX                            63              Unresectable                     NR                   NR
  Wein A. et al             2003   prospective     20            FOLFOX                            62.5            Resectable                       NR                   NR

Abbreviations: PFS, progression free survival; ORR, objective response rate; FOXFOX, oxaliplatin plus leucovorin plus fluorouraci; FOLFIRI, irinotecan plus leucovorin plus fluorouraci; Xelox, xeloda plus oxaliplatin; XEFIRI, xeloda plus irinotecan; FOLFOXIRI, irinotecan plus oxaliplatin plus leucovorin plus fluorouraci; NR, not reported;

![Selected methodological quality indicator](oncotarget-06-44005-g002){#F2}

Pooled incidence of primary outcomes {#s2_2}
------------------------------------

A total of 1755 patients were included for ORR analysis. The pooled event rate of ORR for NCT plus bevacizumab and NCT plus anti-epidermal growth-factor receptor (EGFR)-monoclonal antibodies (MoAbs) were 66.2% and 66.2% respectively, which was higher than that of NCT alone (43.4%, Figure [3](#F3){ref-type="fig"}). A higher incidence of hepatic resection and R0 hepatic resection was observed in NCT plus bevacizumab (68.4% and 49.2% respectively) when compared to NCT plus anti-EGFR-MoAbs or NCT alone. While comparable incidence of hepatic resection and R0 hepatic resection was found between NCT plus anti-EGFR-MoAbs and NCT alone (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![Incidence of objective response rate according to neoadjuvant regimens](oncotarget-06-44005-g003){#F3}

![Incidence of hepatic resection rate according to neoadjuvant regimens](oncotarget-06-44005-g004){#F4}

![Incidence of R0 hepatic resection rate according to neoadjuvant regimens](oncotarget-06-44005-g005){#F5}

Efficacy comparison between NCT plus targeted agents and NCT {#s2_3}
------------------------------------------------------------

In comparison with NCT alone, NCT plus bevacizumab or anti-EGFR-MoAbs significantly improve ORR (RR 1.53, 95% CI 1.30--1.80; *p* \< 0.001; RR 1.53, 95% CI: 1.27--1.83, *p* \< 0.001; respectively), NCT plus bevacizumab significantly improved R0 hepatic resection rate in comparison with NCT alone (RR 1.61, 95% CI: 1.27--2.04, *p* \< 0.001), but not for overall hepatic resection rate (RR 1.26, 95% CI: 0.81--1.94, *p* = 0.30). While hepatic resection rate and R0 hepatic resection rate was comparable between NCT plus anti-EGFR-MoAbs and NCT alone (* p* = 0.42 and *p* = 0.37, respectively) (Table [2](#T2){ref-type="table"}).

###### Comparison of primary outcomes for NCT plus target agents versus NCT alone

  Groups                      Cohorts (n)   Patients (n)   Events (95%)        *I*^2^   Relative risk (95%)   *p*
  --------------------------- ------------- -------------- ------------------- -------- --------------------- ---------
  ORR                                                                                                         
   NCT                        8             549            43.4 (37.8--49.1)   33.5     1                     −
   NCT plus bevacizumab       15            666            66.2 (59.5--72.4)   64.5     1.53 (1.30--1.80)     \<0.001
   NCT plus EGFR- MoAb        8             560            66.2 (57.6--73.9)   73.3     1.53 (1.27--1.83)     \<0.001
  Hepatic resection rate                                                                                      
   NCT                        9             602            54.5 (34.8--72.9)   93.5     1                     −
   NCT plus bevacizumab       8             337            68.4 (51.6--81.4)   85.2     1.26 (0.81--1.94)     0.30
   NCT plus EGFR- MoAb        7             481            51.8 (34.0--69.2)   92.5     0.95 (0.57--1.59)     0.42
  R0 hepatic resection rate                                                                                   
   NCT                        5             216            30.6 (24.8--37.0)   93.6     1                     −
   NCT plus bevacizumab       8             285            49.2 (43.0--55.5)   91.7     1.61 (1.27--2.04)     \<0.001
   NCT plus EGFR- MoAb        7             232            31.9 (27.5--36.7)   3.2      1.04 (0.81--1.33)     0.37

*I*^2^ ≥ 50% suggests high heterogeneity across studies.

Abbreviation: NCT = neoadjuvant chemotherapy; ORR, objective response rate;

Sub-group analysis {#s2_4}
------------------

Six included trials reported efficacy data about anti-EGFR-MoAbs according to K-ras status in CRLM patients. The pooled ORR, hepatic resection and R0 hepatic resection rate for CRLM with K-ras wild-type receiving EGFR-MoAbs were 64.6% (95% CI: 59.8--69.0%), 56.7% (95% CI: 33.7--77.2%), and 30.0% (95% CI: 24.2--36.4%), respectively. Then, we performed sub-groups analysis according to respectability status. For initially resectable CRLM patients, the addition of targeted agents to NCT did not significantly improve hepatic resection rate (88.9% versus 82.5%) and R0 hepatic resection rate (67.5% versus 69.7%), while the addition of targeted agents to NCT increased ORR (65.0% versus 44.3%), hepatic resection rate (54.8% versus 35.5%) and R0 hepatic resection rate (38.0% versus 18.3%) in comparison to NCT alone (Table [3](#T3){ref-type="table"}). Additionally, we performed sub-groups analysis based on combined chemotherapy. Irinotecan-based NCT plus targeted agents seemed to improve hepatic resection rate and R0 hepatic resection rate when compared to NCT alone (Table [3](#T3){ref-type="table"}). However, only one trial investigating FOLFIRI plus bevacizumab in resectable CRLM patients was included for analysis, thus further studies were still needed to assess the efficacy of irinotecan-based NCT plus targeted agents in CRLM patients. For CRLM patients receiving oxaliplatin-based NCT, the addition of targeted agents to oxaliplatin-based chemotherapy increased ORR (65.1% versus 46.3%), but not for hepatic resection rate and R0 hepatic resection rate (Table [3](#T3){ref-type="table"}).

###### Sub-group analysis of efficacy for NCT plus target agents versus NCT alone

  Groups              ORR                   Hepatic resection rate   R0 hepatic resection rate                                               
  ------------------- --------------------- ------------------------ --------------------------- --------------------- --------------------- ---------------------
   Resectable         48.8% (27.3--70.7%)   68.2% (61.5--74.2%)      82.5% (50.2--95.6%)         88.9% (82.7--93.1%)   69.7% (31.7--92.0%)   67.5% (21.5--94.0%)
   Unresectable       44.3% (39.0--49.8%)   65.0% (62.3%-71.0%)      35.5% (24.7--48.0%)         54.8% (42.1--66.9%)   18.3% (10.1--30.9%)   38.0% (26.7--50.8%)
  Chemotherapy                                                                                                                               
  Irinotecan-based    43.8% (36.4--51.6%)   55.4% (41.4--68.7%)      54.3% (24.5--81.4%)         94.9% (81.7--98.7%)   57.3% (7--96%)        84.6% (69.7--92.9%)
  Oxaliplatin-based   46.3% (31.4--61.8%)   65.1% (58.3--71.3%)      57.8% (22.3--86.7%)         53.3% (48.8--57.8%)   58.9% (17.4--90.7%)   36.5% (31.9--41.3%)

Abbreviation: NCT, neoadjuvant chemotherapy; ORR, objective response rate;

DISCUSSION {#s3}
==========

The liver is the common metastatic site for colorectal cancer, and surgical resection is the only therapeutic modality that offers the potential for long-term cure. Appropriate patient selection for surgery and improvements in perioperative care has resulted in low morbidity and mortality rates, meaning that this is the therapy of choice in suitable patients. In recent years, the survival of patients with metastatic colorectal cancer has been improved, initially by the use of oxaliplatin- or irinotecan-based combination chemotherapy. Subsequently, it has been shown that the efficacy of cytotoxic chemotherapy can be enhanced by the addition of novel targeted agents, notably the anti-VEGF monoclonal antibodies and the anti-EGFR antibodies. However, the efficacy of targeted agents in neoadjuvant chemotherapy for CRLM patients remains unknown. Recently, two prospective randomized controlled trials have been conducted to investigate the efficacy of NCT plus cetuximab versus NCT alone in CRLM patients \[[@R33]\]. The trial conducted by Ye L.C et al showed that cetuximab combined with chemotherapy improved the resectability of liver metastases and improved response rates (57.1% versus 29.4%) and 3-year survival (41% versus 18%) in comparison with chemotherapy alone for K-RAS wild-type CRLM patients \[[@R33]\], while the New EPOC trial showed that the addition of cetuximab to neoadjuvant chemotherapy for K-RAS wild-type CRLM patients resulted in shorter progression-free survival (HR 1.48, 95% CI: 1.04--2.12, *p* = 0.03) \[[@R29]\]. Therefore, the role of cetuximab in neoadjuvant setting for CRLM patients is not established. In addition, to the best of our knowledge, there is lack of head-to-head comparison data available for NCT plus bevacizumab versus NCT alone in the treatment of CRLM patients. As a result, we conduct this systematic review and meta-analysis to evaluate the efficacy of NCT plus targeted agents versus NCT alone for the treatment of CRLM patients.

A total of 2099 CRLM patients from 40 cohorts are included for analysis. Based on our pooled results, we find that NCT plus bevacizumab could employ a role in the neoadjuvant setting for CRLM patients in particular in terms of ORR and R0 hepatic resection rate, while comparable efficacy is found between NCT plus EGFR-MoAbs and NCT alone in terms of hepatic resection rate and R0 hepatic resection rate. Additionally, several retrospective studies have demonstrated that the addition of bevacizumab to chemotherapy in the neoadjuvant and conversion setting significantly improve pathological response in CRLM patients, and patients with a good pathological response to neoadjuvant chemotherapy are associated with a better outcome \[[@R41], [@R55], [@R56]\]. Based on these encouraging data, the combination of NCT plus bevacizumab as neoadjuvant and conversion therapy could be recommended for initially unresectable or resectable CRLM patients due to its higher ORR and R0 hepatic resection rate. However, more evidence is still required before NCT plus bevacizumab could become the standard peri-operative treatment for these patients.

We then perform sub-group analysis according to patients\' characteristics. Our results find that the addition of targeted agents to NCT seems more efficient for initially unresectable patients than for initial resectable patients in terms of hepatic resection rate and R0 hepatic resection rate. It might be explained that the addition of targeted agents to NCT could increase the efficacy of neoadjuvant treatment in initially unresectable CRLM patients, which might achieve maximum tumor shrinkage to create an opportunity for hepatic resection. and it has been reported that rate of early tumor shrinkage is directly associated with the ability to operate and has also been proven to be associated with long-term survival \[[@R57]\]. The optimal chemotherapy regimen combined with targeted agents as neoadjuvant therapy for CRLM patients remains to be defined. We thus carry out a sub-group analysis stratified according to chemotherapy regimens. Our results find that irinotecan-based NCT plus targeted agents seems to improve hepatic resection rate and R0 hepatic resection rate when compared to NCT alone, while the addition of targeted agents to oxaliplatin-based NCT does not improve hepatic resection rate and R0 hepatic resection rate. A similar result have been observed in a large prospective clinical trials comparing FOLFOX versus FOLRIR as first-line treatment for metastatic colorectal cancer \[[@R58]\]. In that study of 220 unselected patients, FOLFIRI achieved a significantly higher rate of secondary surgery to remove metastases as compared to FOLFOX (22% vs. 9%; *P* = 0.02), with a higher R0 rate (13% vs 7%), which adding further validity to our findings. However, the results of our sub-group analysis regarding concurrent chemotherapy on efficacy of targeted agents are not solid since only one trial investigating FOLFIRI plus bevacizumab in resectable CRLM patients is included for analysis, thus more studies are still needed to assess the efficacy of irinotecan-based NCT plus targeted agents in those patients. We also investigate the efficacy of anti-EGFR-MoAbs in CRLM with K-ras wild-type. And the pooled ORR, hepatic resection and R0 hepatic resection rate for CRLM with K-ras wild-type is comparable to those for CRLM patients with or without K-ras wild-type. One possible explanation for this is that although these studies include CRLM patients with or without k-ras wild type, most of CRLM patients have k-ras wild type. For example, 81% CRLM patients had k-ras wild-type tumor in the trial conducted by Garufi C. et al \[[@R46]\]. Another possible explanation for this finding is that all RAS wild-type patients receiving anti-EGFR agents have a better efficacy than for patients with only KRAS exon 2 wild type, while patients in these previous trials did not detect other new RAS status including NRAS and exons 3 and 3 of KRAS, which might also be negative predictive biomarkers for anti-EGFR agents \[[@R57]\]. Moreover, we could not pool the results about quality of life (QoL) due to none of included trial reporting Qol results.

Several limitations exist in this analysis. First and most importantly, the application of formal meta-analytic methods to observational studies has been controversial \[[@R59]\]. One of the most important reasons for this is that the designs and populations of the studies are diverse, and that these differences may influence the pooled estimates. However, when no head-to-head comparison data available for NCT plus bevacizumab versus NCT alone, a meta-analysis of observational studies is one of the few methods for assessing efficacy \[[@R60]\]. Second, the study is a pooled analysis of primarily single arm prospective studies and retrospective series, with a small number of patients included that might have over-reported the benefit of preoperative treatments. The inclusion criteria also likely favor young, fit, and responder patients, a highly selected group of subjects with good prognostic indicators. Thirdly, this meta-analysis only considers published literature, and lack of individual patient data prevents us from adjusting the treatment effect according to disease and patient variables. Finally, we could not pool the results about QoL due to none of included trial reporting Qol results.

MATERIALS AND METHODS {#s4}
=====================

Study design {#s4_1}
------------

We developed a protocol that defined inclusion criteria, search strategy, outcomes of interest, and analysis plan. The reporting of this systematic review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements \[[@R18]\].

Identification and selection of studies {#s4_2}
---------------------------------------

To identify studies for inclusion in our systematic review and meta-analysis, we did a broad search of four databases, including Embase, Medline, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from the date of inception of every database to August 2014. The search included the following terms: "colorectal neoplasms", "colorectal cancer", "colorectal carcinoma", "cetuximab", "panitumumab", "bevacizumab", "aflibercept", "targeted agents", "neoadjuvant chemotherapy" and "perioperative chemotherapy". Additional references were searched through manual searches of the reference lists and specialist journals. No language restrictions were applied.

To be eligible for inclusion in our systematic review and meta-analysis, study populations (referred to hereafter as cohorts) had to meet all the following criteria: 1) patients with colorectal liver metastasis; 2) treatment with neoadjuvant chemotherapy, NCT plus approved molecular agents (cetuximab, bevacizumab, panitumumab and aflibercept); 3) reported outcomes of interest (ie, objective response rate, overall resection rate, and R0 liver resection rate); and 4) from an original study (ie, randomized controlled trial, non-randomized clinical trial, observational studies, or case series).

Data extraction {#s4_3}
---------------

Two investigators screened the titles and abstracts of potentially relevant studies. We retrieved the full text of relevant studies for further review by the same two reviewers. A third senior investigator resolved any discrepancies between reviewers. If reviewers suspected an overlap of cohorts in a report, they contacted the corresponding author for clarification; we excluded studies with a clear overlap.

The same pair of reviewers extracted study details independently, using a standardized pilot-tested form. A third investigator reviewed all data entries. We extracted the following data: author, study design, study period, median age, interventions (neoadjuvant chemotherapy regimens and dose), sample size and outcomes of interest. We defined outcomes of interest as overall resection rate, R0 liver resection rate and objective response rate (ORR). ORR was defined as the sum of partial and complete response rates according to the Response Evaluation Criteria in Solid Tumors \[[@R19]\]. To assess quality, since we included non-comparative (uncontrolled) studies in our systematic review and meta-analysis, we used the Newcastle-Ottawa quality assessment scale \[[@R20]\]. We selected items that focused on representativeness of study patients, demonstration that the outcome of interest was not present at the start of the study, adequate assessment of outcome, sufficient length of follow-up to allow outcomes to arise, and adequacy of follow-up.

Statistical analysis {#s4_4}
--------------------

We prespecified the analysis plan in the protocol. We analyzed all patients who started NCT or NCT plus targeted agents, regardless of their adherence to treatment. We calculated event rates of outcome (the proportion of patients who developed outcomes of interest) from the included cohorts for both NCT and NCT plus targeted agents. We pooled log-transformed event rates with DerSimonian and Laird random-effect models or using the Mantel-Haenszel test according to heterogeneity among included studies \[[@R21]\]. We used the test of interaction proposed by Altman and Bland to compare log-transformed rates of outcomes between NCT and NCT plus targeted agents \[[@R22]\]. A statistical test with a *p*-value less than 0.05 was considered significant. To account for the potential effect of publication bias, we used the Duval and Tweedie non-parametric trim-and-fill method \[[@R23]\]. To measure overall heterogeneity across the included cohorts, we calculated the *I*^ 2^ statistic, with *I*^ 2^ greater than 50% indicating high heterogeneity. We assessed potential publication bias by visual inspection of the symmetry of funnel plots and with the Egger regression asymmetry test. We did all statistical analyses with comprehensive meta-analysis software version 2.0(Biostat, Englewood, NJ, USA).

CONCLUSIONS {#s5}
===========

Currently available clinical evidence indicates that NCT plus bevacizumab may be a feasible regimen for patients with CRLM in comparison with NCT alone. However, since the overall quantity and quality of data regarding NCT plus bevacizumab is poor and considering the risk of bias in comparisons between observation studies. The reported results do not allow for definite conclusions. As a result, prospective randomized studies, definitively comparing the survival and treatment toxicity between NCT plus bevacizumab and NCT alone, are strongly encouraged to clearly set the role of NCT plus bevacizumab in the treatment of CRLM patients.
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